Mariia Gennadievna Shvydkaia¹*, Alexander Mikhailovich Zatevalov¹, Sergei Dmitrievich Mitrokhin², Jamilya Temirlanovna Dzhandarova³ and Pavel Sergeevich Mayorov⁴

¹G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology, Rospotrebnadzor, Moscow, Russia

*Corresponding Author: Mariia Gennadievna Shvydkaia, G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology, Rospotrebnadzor, Moscow, Russia.

Received: December 30, 2021; Published: March 18, 2022

Abstract

Diarrhea is one of the common symptoms in the treatment of cancer patients. Improving the preventive and therapeutic treatment of diarrhea can be made through a better understanding of risk factors for this disease in the pediatric oncology hospital. 503 stool samples of patients were examined by the bacteriological and ELISA methods (to determine the Clostridioides difficile toxin A/B) in feces followed by analysis of 187 case histories of these patients retrospectively. Clostridioides difficile, Clostridium perfringens, Klebsiella sp., Citrobacter sp., Enterobacter sp., Enterococcus sp., Pseudomonas aeruginosa can cause diarrhea in children, particularly in patients of pediatric oncological hospital. There is a significant change in the composition of intestinal flora in patients with diarrhea; especially important is a decrease in Escherichia coli. The effect of nitroimidazoles (metronidazole) on the development of diarrhea in a pediatric oncological hospital was noted. Stool samples from all patients at the pediatric oncological center who have diarrhea, and especially those receiving chemotherapy and nitroimidazoles (metronidazole), should be regularly sent for testing to determine the exact cause of the diarrhea.

Keywords: Diarrhea; Children; Chemotherapy; Microbiome; Clostridioides difficile Infection

References

1. Qasim A., et al. “Neutropenic Enterocolitis (Typhlitis)”. StatPearls. Treasure Island (FL): StatPearls Publishing (2020).
2. Buchheidt D., et al. “Diagnosis and treatment of documented infections in neutropenic patients recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)”. Annals of Hematology 82 (2003): S127-S132.
3. Lim SC., et al. “Clostridium difficile and One Health”. Clinical Microbiology and Infection7 (2019): 857-863.
4. DicksL MT., et al. “Clostridium difficile, the Difficult "Kloster" Fuelled by Antibiotics”. Current Microbiology6 (2019): 774-782.
5. Shafiq M., et al. “Effects of co-infection on the clinical outcomes of Clostridium difficile infection”. Gut Pathogen9 (2020).
6. Lees EA., et al. “LeesThe role of Clostridium difficile in the paediatric and neonatal gut - a narrative review”. European Journal of Clinical Microbiology and Infectious Diseases 35 (2016): 1047-1057.
7. Lees EA., et al. “Characterization of Circulating Clostridium difficile Strains, Host Response and Intestinal Microbiome in Hospitalized Children With Diarrhea”. The Pediatric Infectious Disease Journal3 (2020): 221-228.
8. de Oliveira Costa P., et al. “Infection with multidrug-resistant gram-negative bacteria in a pediatric oncology intensive care unit: risk factors and outcomes”. Jornal de Pediatria5 (2015): 435-441.
9. Vervoort J., et al. “High rates of intestinal colonisation with fluoroquinolone-resistant ESBL-harbouring Enterobacteriaceae in hospitalised patients with antibiotic-associated diarrhoea”. European Journal of Clinical Microbiology and Infectious Diseases 33 (2014): 2215-2221.
10. Krishnamurthi SS., et al. “Management of acute chemotherapy-related diarrhea”. UpToDate (2019).
11. Sherief LM., et al. “Diarrhea in neutropenic children with cancer: An Egyptian center experience, with emphasis on neutropenic enterocolitis”. Indian Journal of Medical and Paediatric Oncology 2 (2012): 95-101.
12. Nesher L., et al. “Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy”. Clinical Infectious Diseases 5 (2013): 711-717.
13. Kaito S., et al. “Fatal Neutropenic Enterocolitis Caused by Stenotrophomonas maltophilia: A Rare and Underrecognized Entity”. Internal Medicine5 (2013): 711-717.
14. Sukhwani KS., et al. “Clinical Profile of Clostridium difficile Associated Diarrhea: A study from Tertiary Care Centre of South India”. Tropical Gastroenterology3 (2018): 135-141.
15. Mazankova LN., et al. “Antibiotic-associated Diarrhea and Cl. difficile-infection in Children: Risk Factors”. Children Infections2 (2015): 29-34.
16. Boronina LG., et al. “Laboratory diagnostics of Clostridium difficile infection of childrens in the multi-field hospital”. Poliklinika 4-1 (2016): 17-20.
17. EUCAST Clinical breakpoints - breakpoints and guidance. European Society of Clinical Microbiology and Infectious Diseases (2021).
18. Nagaro KJ., et al. “Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile”. Antimicrobial Agents and Chemotherapy11 (2013): 5266-5270.
19. Martirosian G., et al. “Isolation of non-toxigenic strains of Clostridium difficile from cases of diarrhea among patients hospitalized in hematology/oncology ward”. The Polish Society of Microbiologists3 (2004): 197-200.
20. Brouwer MS., et al. “Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers”. Nature Communication 4 (2013): 2601.
21. Zhang L., et al. “Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic difficile colonization”. Anaerobe 34 (2015): 1-7.
22. Theriot CM., et al. “Interactions Between the Gastrointestinal Microbiome and Clostridium difficile". Annual Review of Microbiology 69 (2015): 445-461.
23. Schubert AM., et al. “Microbiome data distinguish patients with Clostridium difficile infection and non- difficile-associated diarrhea from healthy controls”. mBio 5 (2014): e01021-1014.
24. Lawley TD., et al. “Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice”. PLoS Pathogen10 (2012): e1002995.
25. Rousseau C., et al. “Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition”. Journal of Clinical Microbiology 3 (2011): 858-865.
26. Fisher A., et al. “A Case Report and Literature Review of Clostridium difficile Negative Antibiotic Associated Hemorrhagic Colitis Caused by Klebsiella oxytoca”. Case Reports in Gastrointestinal Medicine 2018 (2018): 4.
27. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment”. Future Microbiology5 (2008): 563-578.
28. Ueda C., et al. “Anti-Clostridium difficile Potential of Tetramic Acid Derivatives from Pseudomonas aeruginosa Quorum-Sensing Autoinducers”. Antimicrobial Agents and Chemotherapy2 (2010): 683-688.
29. Boyanova L., et al. “Clostridioides (Clostridium) difficile carriage in asymptomatic children since 2010: a narrative review”. Biotechnology and Biotechnological Equipment1 (2019): 1228-1236.
30. Schubert AM., et al. “Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls”. mBio 3 (2014): e01021.
31. Peng Z., et al. “Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing”. Journal of Clinical Microbiology7 (2017): 1998-2008.
32. Bayasi G., et al. “The Effect of Intravenous Vancomycin in the Reduction of the Incidence of Clostridium difficile Colitis”. Journal of Infectious Diseases and Therapy 4 (2016): 286.

Citation

Citation: Mariia Gennadievna Shvydkaia., et al. “Infection and Non-infection Cause of Diarrhea in Child Patients an Oncological Clinic". Acta Scientific Microbiology 5.4 (2022): 81-90.

Copyright

Copyright: © 2022 Mariia Gennadievna Shvydkaia., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.